a year ago
SANA
AnalystsEmily BodnarEmily Bodnar's Stock Forecasts
AnalystsEmily Bodnar
Sectors:
Analyst Ranking
Bottom 5%
#4982 out of 5192 analysts
Average Return
-2.58%
Win Rate
27%86 out of 322
Risk vs Reward
Poor
Good
Emily Bodnar's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Rapt Therapeutics IncRAPT | +738.60% | $6.87 | $57.57 | 2025-05-21 - 2026-01-20 | Buy |
Rapt Therapeutics IncRAPT | +567.87% | $8.62 | $57.57 | 2025-07-09 - 2026-01-20 | Buy |
Olema Pharmaceuticals IncOLMA | +477.86% | $4.11 | $23.75 | 2025-03-18 - 2026-02-12 | Buy |
Olema Pharmaceuticals IncOLMA | +457.51% | $4.26 | $23.75 | 2025-03-04 - 2026-02-12 | Buy |
Olema Pharmaceuticals IncOLMA | +448.50% | $4.33 | $23.75 | 2025-03-10 - 2026-02-12 | Buy |
Emily Bodnar Analyst Color
Get additional color on Emily Bodnar's coverage of popular stocks
2 years ago
FEMY
Emily Bodnar's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Agios Pharmaceuticals IncAGIO | 5 | Buy | $65.00 | +131.56% | Maintains | a day ago |
Novocure LtdNVCR | 21 | Buy | $47.00 | +275.10% | Maintains | 2 days ago |
Arcellx IncACLX | 14 | Buy | $115.00 | +67.52% | Reiterates | 9 days ago |
Rapt Therapeutics IncRAPT | 4 | Hold | $58.00 | +0.31% | Downgrades | 24 days ago |
Ventyx Biosciences IncVTYX | 15 | Hold | $14.00 | +0.50% | Downgrades | a month ago |
Vtv Therapeutics IncVTVT | 3 | Buy | $47.00 | +28.80% | Maintains | 2 months ago |
Arcus Biosciences IncRCUS | 7 | Buy | $32.00 | +60.32% | Maintains | 2 months ago |
Olema Pharmaceuticals IncOLMA | 22 | Buy | $45.00 | +89.47% | Maintains | 2 months ago |
Acrivon Therapeutics IncACRV | 12 | Buy | $19.00 | +1,102.53% | Reiterates | 3 months ago |
Anaptysbio IncANAB | 12 | Buy | $51.00 | -7.10% | Maintains | 3 months ago |
Artiva Biotherapeutics IncARTV | 2 | Buy | $15.00 | +275.94% | Maintains | 3 months ago |
Sana Biotechnology IncSANA | 11 | Buy | $9.00 | +137.47% | Maintains | 3 months ago |
Context Therapeutics IncCNTX | 11 | Buy | $5.00 | +105.76% | Maintains | 3 months ago |
Senti Biosciences IncSNTI | 1 | Buy | $12.00 | +1,381.48% | Initiates Coverage On | 4 months ago |
Tg Therapeutics IncTGTX | 1 | Buy | $60.00 | +111.12% | Assumes | 4 months ago |
Agenus IncAGEN | 14 | Buy | $23.00 | +707.02% | Reiterates | 5 months ago |
Briacell Therapeutics CorpBCTX | 15 | Buy | $40.00 | +876.80% | Maintains | 6 months ago |
Mink Therapeutics IncINKT | 14 | Buy | $35.00 | +217.03% | Upgrades | 6 months ago |
Femasys IncFEMY | 25 | Buy | $8.00 | +1,532.65% | Maintains | 6 months ago |
Sab Biotherapeutics IncSABS | 2 | Buy | $9.00 | +118.45% | Maintains | 7 months ago |
Jasper Therapeutics IncJSPR | 10 | Buy | $20.00 | +1,609.40% | Maintains | 7 months ago |
Nextcure IncNXTC | 9 | Buy | $36.00 | +171.90% | Reiterates | 7 months ago |
Transcode Therapeutics IncRNAZ | 17 | Buy | $280.00 | +2,734.01% | Maintains | 10 months ago |
Connect Biopharma Holdings LtdCNTB | 6 | Buy | $8.00 | +223.89% | Reiterates | 10 months ago |
Io Biotech IncIOBT | 13 | Buy | $12.00 | +3,280.28% | Reiterates | 10 months ago |
Genelux CorpGNLX | 7 | Buy | $30.00 | +1,104.82% | Reiterates | 10 months ago |
Nkarta IncNKTX | 13 | Buy | $18.00 | +813.71% | Reiterates | a year ago |
Imunon IncIMNN | 13 | Buy | $210.00 | +6,322.02% | Reiterates | a year ago |
Atossa Therapeutics IncATOS | 13 | Buy | $35.00 | +788.32% | Reiterates | a year ago |
Acelyrin IncSLRN | 13 | Hold | $6.00 | N/A | Maintains | a year ago |
Geron CorpGERN | 3 | Buy | $9.00 | N/A | Reiterates | a year ago |
Purple Biotech LtdPPBT | 13 | Buy | $33.00 | N/A | Reiterates | a year ago |
Gracell Biotechnologies IncGRCL | 6 | Hold | $10.00 | N/A | Downgrades | 2 years ago |
Dice Therapeutics IncDICE | 8 | Hold | $48.00 | N/A | Reiterates | 3 years ago |
Sqz Biotechnologies CoSQZB | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.